FIND A PROTON CENTER
National Association for Proton Therapy National Association for Proton Therapy National Association for Proton Therapy National Association for Proton Therapy
  • ABOUT
    • About NAPT
    • Our Advocacy
    • Leadership
    • Awards
    • Corporate Partners
    • Join NAPT
  • PROTON THERAPY
    • History
    • FAQ
    • Pediatric Proton Therapy
  • FOR PATIENTS
    • Find A Proton Center
    • Patient Stories
    • Clinical Trials
    • Resource Center
  • FOR PROVIDERS
    • Clinical Research
    • Clinical Trials
  • EVENTS
  • NEWS
    • NAPT News
    • Proton Therapy In The News
National Association for Proton Therapy National Association for Proton Therapy
  • ABOUT
    • About NAPT
    • Our Advocacy
    • Leadership
    • Awards
    • Corporate Partners
    • Join NAPT
  • PROTON THERAPY
    • History
    • FAQ
    • Pediatric Proton Therapy
  • FOR PATIENTS
    • Find A Proton Center
    • Patient Stories
    • Clinical Trials
    • Resource Center
  • FOR PROVIDERS
    • Clinical Research
    • Clinical Trials
  • EVENTS
  • NEWS
    • NAPT News
    • Proton Therapy In The News
Nov 17

Insurance Delays and Denials Impede Vital Cancer Treatment

  • November 17, 2023

Cancer is a disease where the passage of time can make a difference in treatment outcomes. Recent research underscores the reality that for cancer patients, each week of delay in starting treatment can increase the risk of death by 1.2% to 3.2%. However, the process of prior authorization, a common practice mandated by health insurance providers, is creating formidable barriers to effective cancer care, extending beyond just proton therapy.

Patients who need proton therapy, a proven life-saving cancer treatment, are among the most affected by these barriers. Health insurance payers are often slow to acknowledge the research supporting higher-reimbursed treatments, leading to a high rate of claim denials. Obtaining insurance approval for patients participating in clinical studies to demonstrate treatment efficacy can be a complex and protracted process, largely due to payer resistance. These challenges collectively restrict access to innovative cancer treatments, such as proton therapy, which have the potential to significantly improve patient outcomes.

While these issues are prominent with proton therapy, they are indicative of a broader problem within the healthcare system. The prior authorization burden extends its reach to many other aspects of cancer treatment, causing delays, financial strain, and emotional distress for patients and healthcare providers.

Let’s examine the key statistics that illustrate the negative impact of prior authorization on the broader cancer treatment landscape:

  • 2% of proton therapy providers face the requirement of prior authorization for more than half of their claims.
  • In 2021, 42.8% of prior authorization requests for proton therapy were initially denied.
  • Medicare Advantage Organizations (MAOs) denied 27% of prior authorization requests for items and services approved by Medicare, double the rate reported by the Office of the Inspector General (OIG) in April 2022.
  • In 2021, 42.8% of prior authorization requests for proton therapy were initially denied.

These figures highlight the widespread challenges faced by cancer patients and healthcare providers due to the prior authorization process, resulting in extended delays and undue burdens on patient care, regardless of the specific treatment modality.

For cancer patients, these delays not only mean a more extended journey to recovery, but can also lead to financial hardship. Physicians report that prolonged prior authorization processes often lead to patients abandoning treatment due to ongoing struggles with payers. These delays may also lead to patients experiencing serious adverse events. Even when providers appeal denials and succeed in getting them overturned, the process causes patients unnecessary stress and prolonged waits.

To address these pressing issues, organizations like the National Association for Proton Therapy (NAPT) are actively working to reform the broken prior authorization process. Their efforts aim to streamline the process, reduce delays, and ensure that patients have timely access to the life-saving treatments they need. Collaborative initiatives like these offer hope for a more efficient and patient-centric healthcare system.

  • Facebook
  • Twitter
  • Reddit
  • Pinterest
  • Google+
  • LinkedIn
  • E-Mail

JOIN US IN BOSTON!

NEWS BY TOPIC

Advocacy Events Member News NAPT Awards NAPT News News Patient Access Patient Stories Payment Stability Pediatric Cancer Press Releases Prior Authorization Proton Therapy In The News Research RO Model State Legislation VA Access

The National Association for Proton Therapy (NAPT) and its members support cancer research and treatment innovation and are committed to raising awareness about the value of proton therapy among policymakers, insurers, caregivers and patients to ensure that this advanced treatment modality is affordable and available in communities across the country.

  • Connected Community Log In
  • Privacy Policy
  • Terms of Use

LATEST NAPT NEWS

  • Insurance Delays and Denials Impede Vital Cancer Treatment
  • The Promise of Proton Therapy: A Ray of Hope for Esophageal Cancer Patients
  • Legal Battle for Life-Saving Cancer Treatment: How One Lawyer Took on Big Insurance to Expose a Broken System
  • Coach Ron Rivera awarded Cancer Support Community’s (CSC) Founders Award, Pledges to Pay It Forward
  • Just Released: 2023 NAPT Member Survey – Executive Summary

CONTACT US

The National Association for Proton Therapy 
PO Box 7801
McLean, VA 22106

202.919.4536

© 2023 National Association for Proton Therapy (NAPT)